Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Upstream Bio (UPB) EBT: 2023-2025

Historic EBT for Upstream Bio (UPB) over the last 2 years, with Sep 2025 value amounting to -$33.7 million.

  • Upstream Bio's EBT fell 110.95% to -$33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$122.2 million, marking a year-over-year decrease of 113.52%. This contributed to the annual value of -$65.6 million for FY2024, which is 82.59% down from last year.
  • Upstream Bio's EBT amounted to -$33.7 million in Q3 2025, which was up 15.50% from -$39.9 million recorded in Q2 2025.
  • Over the past 5 years, Upstream Bio's EBT peaked at -$7.9 million during Q3 2023, and registered a low of -$39.9 million during Q2 2025.
  • For the 3-year period, Upstream Bio's EBT averaged around -$20.8 million, with its median value being -$16.0 million (2024).
  • Data for Upstream Bio's EBT shows a maximum YoY slumped of 172.22% (in 2025) over the last 5 years.
  • Upstream Bio's EBT (Quarterly) stood at -$12.8 million in 2023, then tumbled by 65.81% to -$21.2 million in 2024, then tumbled by 110.95% to -$33.7 million in 2025.
  • Its EBT stands at -$33.7 million for Q3 2025, versus -$39.9 million for Q2 2025 and -$27.3 million for Q1 2025.